Estrella Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021
Cash & Equivalents	2.48	0.04	0.01
Short-Term Investments	0.27	0	0
Cash & Cash Equivalents	2.75	0.04	0.01
Cash Growth	6645.29%	270.32%	-
Other Current Assets	0	0.01	0
Total Current Assets	2.75	0.05	0.01
Long-Term Investments	0	9.67	3.19
Other Long-Term Assets	0.28	0	0.24
Total Long-Term Assets	0.28	9.67	3.43
Total Assets	3.03	9.72	3.44
Accounts Payable	9.33	0.33	0
Current Debt	0	0.5	0.18
Other Current Liabilities	0.43	0.25	0.05
Total Current Liabilities	9.76	1.07	0.23
Other Long-Term Liabilities	0.01	1.58	3.19
Total Long-Term Liabilities	0.01	1.58	3.19
Total Liabilities	9.77	2.65	3.42
Total Debt	0	0.5	0.18
Debt Growth	-	177.00%	-
Retained Earnings	-12.19	-2.26	-0
Shareholders' Equity	-11.74	-2.26	0.02
Net Cash / Debt	2.75	-0.46	-0.17
Net Cash Per Share	2.17	-0.08	-0.17
Working Capital	-7.01	-1.02	-0.22
Book Value Per Share	-9.25	-0.39	0.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).